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Abstract 
Background  Klotho proteins (α- and β) are membrane-based circulating proteins that regulate cell metabolism, as well as the lifespan 
modulating activity of Fibroblast Growth Factors (FGFs). Recent data has shown that higher plasma circulating Klotho levels reduce cardio-
vascular risk, suggesting Klotho has a protective role in cardiovascular diseases. However, although so far it has been identified in various 
organs, it is unknown whether cardiomyocytes express Klotho and FGFs, and whether high cardiovascular risk could affect cardiac expres-
sion of Klotho, FGFs and other molecules. Methods  We selected 20 patients with an estimated 10-year high atherosclerotic cardiovascular 
disease and 10 age-matched control subjects with an estimated 10-year low risk undergone cardiac surgery for reasons other than coronary 
artery by-pass. In myocardial biopsies, we evaluated by immuno-histochemistry whether Klotho and FGFs were expressed in cardiomyo-
cytes, and whether higher cardiovascular risk influenced the expression of other molecules involved in endoplasmic reticulum stress, oxida-
tive stress, inflammation and fibrosis. Results  Only cardiomyocytes of patients with a higher cardiovascular risk showed lower expression 
of Klotho, but higher expressions of FGFs. Furthermore, higher cardiovascular risk was associated with increased expression of oxidative 
and endoplasmic reticular stress, inflammation and fibrosis. Conclusions  This study showed for the first time that Klotho proteins are ex-
pressed in human cardiomyocytes and that cardiac expression of Klotho is down-regulated in higher cardiovascular risk patients, while ex-
pression of stress-related molecules were significantly increased. 
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1  Introduction 
Several conditions such as diabetes, dyslipidemia, hy-
pertension and obesity are well-established risk factors for 
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cardiovascular damage and coronary artery disease. However, 
the susceptibility, severity and progression of coronary disease 
are not fully explicable by these established risk factors and 
additional biological systems could potentially be involved in 
the genesis and progression of vascular atherosclerotic min-
eralization. Among these, the role of Klotho, fibroblast 
growth factors (FGFs) and related stress proteins has 
aroused considerable interest as mediators of coronary athe-
rosclerosis and cardiomyocytes metabolic impairment.[1] 
Klotho is a single-pass trans-membrane protein with a 
long extracellular domain and a short cytoplasmic tail. Two 
distinct forms have been currently identified: (1) α-Klotho 
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(also referred to simply as Klotho), found in many organs 
including kidney, parathyroid gland, brain, adipose tissue 
and small intestine, and (2) β-Klotho, a protein that shares 
41% amino acid identity with α-Klotho, and is expressed in 
adipose tissue, pancreas and liver. The extra-cellular domain 
of both Klotho may be cleaved and released into the blood, 
cerebrospinal fluid and urine as a soluble form.[2] It has been 
suggested that Klotho proteins (trans-membrane and circu-
lating) influence the endocrine activity of FGFs, regulate 
mineral transport and cell metabolism preventing organ 
aging an death.[3] 
Several experimental and clinical studies show that Klotho 
and FGFs are involved in the genesis and progression of 
various cardiovascular diseases,[3–5] preventing oxidative 
stress and so apoptosis and cell death.[6–9] However, it has 
not been clear whether Klotho is constitutionally expressed 
in human cardiomyocytes until now. 
Considering the beneficial physiological functions of 
Klotho on cell metabolism and survival, we hypothesized 
that these molecules could be constitutionally expressed by 
human cardiomyocytes. We used immuno-histochemistry 
techniques, which penalizes protein quantification but lo-
cates these molecules more precisely in the different cell 
types of the myocardial tissue. We investigated whether α- 
and β-Klotho, FGFs (FGF21 and FGF23) were present in 
human cardiomyocytes and whether patients with higher 
cardiovascular risk (HCVR), estimated according to the 
2013 ACC/AHA guidelines on the Assessment of Cardio-
vascular Risk, had altered Klotho, FGFs and any related 
stress molecules expression. 
Recent experimental data has shown that Klotho attenu-
ates endoplasmic reticulum (ER) stress and stress-induced 
apoptosis.[10–12] Indeed, many cardiovascular diseases affect 
the ER ability to synthesize, fold and sort proteins, increas-
ing the expression of molecular chaperones that promote 
proper folding and cellular recovery.[13–16] We therefore 
evaluated the presence of chaperone GRP78, a marker of 
ER stress, in cardiomyocytes. The increase expression of 
GRP78 is induced by enhanced oxidative stress. Given that 
oxygen free radicals are scavenged by superoxide dismu-
tase-1 (SOD1) that act as a molecular switch to activate the 
ER stress response and play an important role in cellular 
homeostasis,[17] we also examined SOD1 modulation. 
Since oxidative stress is related to the inflammatory re-
sponse, we also examined the presence of inducible-NOS 
(iNOS), endothelial-NOS (eNOS) and nuclear factor-kappa-B 
(NF-kB) proteins, which are molecules involved in the in-
tracellular oxidative and inflammatory processes in cardio-
vascular diseases.[18–20] Interestingly, these molecules are 
regulated by Klotho.[4,21–23] 
Finally, it has been shown that Klotho inhibits trans-
forming growth factor-β1 (TGF-β1) signaling, and sup-
pressed experimentally induced fibrosis.[24,25] On the basis 
of these findings, we measured the degree of myocardial 
fibrosis by Sirius Red histochemistry and anti-TGF-β1 
staining. 
2  Methods 
2.1  Patient population 
This research was carried out in accordance with the 
Code of Ethics of the World Medical Association (Declara-
tion of Helsinki). The study was approved by the institu-
tional ethics committees of the local health authority (ASL, 
Brescia, Italy, No.: 5/2008). Informed consent was obtained 
from all individual participants included in the study. 
Ten year atherosclerotic cardiovascular disease (ASCVD) 
risk was estimated using the Risk Estimator application 
available online. This Risk Estimator is intended as a com-
panion tool to the 2013 ACC/AHA Guideline on the As-
sessment of Cardiovascular Risk and the 2013 ACC/AHA 
Guideline on the Treatment of Blood Atherosclerotic Car-
diovascular Risk in Adults. It is able to estimate 10-years 
cardiovascular disease. The information required to estimate 
ASCVD risk includes: age (from 40 to 79 years), sex, race, 
total cholesterol, high-density lipoprotein cholesterol (HDL), 
systolic blood pressure, blood pressure lowering medication 
use, diabetes status and smoking status.[26,27] 
Patients who have a high 10-year ASCVD of 7.5 risk, 
means that 7.5% of them would be expected to have artery 
diseases within the next 10 years. On the contrary, 10-year 
ASCVD risk estimated < 5 refers to low risk patients who 
have a probability to developed cardiovascular diseases in 
the next 10 years less than 5%. 
Thirty strictly selected adult patients undergoing cardiac 
surgery were recruited between 2012 and 2015. They had 
undergone cardiac surgery for reasons other than coronary 
artery by-pass, such as aortic aneurism or atrial myxoma. 
Patients (n = 20) with an estimated high 10-year ASCVD 
risk were included in the HCVR group and age-matched 
patients (n = 10) with an estimated low 10-year ASCVD 
risk were included in Control group. All patients in both 
groups were statin-naïve and had normal coronary arteries 
(by left heart catheterization). Patient exclusion criteria in-
cluded: reduced ejection fraction, enlargement or hypertro-
phy of cardiac chambers, previous myocardial infarct, ar-
rhythmia, concomitant liver, inflammatory, autoimmune, 
endocrine, pulmonary or kidney diseases, myopathy and/or 
basal creatine phosphate kinase increase and chronic hy-
percholesterolemia that required statin administration. These  
Corsetti G, et al. Klotho expression in patients with CVD 703 
  
http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology  
Table 1.  Patient demographics and clinical data. 
 CTRL, n = 10 HCVR, n = 20 
Age, yrs 55.3 ± 2.2 56.0 ± 1.5 
BMI, kg/m2 25.2 ± 1.5 30.3 ± 1.7* 
Systolic blood pressure, mmHg 124.9 ± 3.3 120.0 ± 2.5 
Diastolic blood pressure, mmHg 82.3 ± 2.4 83.5 ± 3.2 
Total cholesterol, mg/dL 200.3 ± 2.6 210.5 ± 1.5 
HDL, mg/dL 73.2 ± 4.0 44.9 ± 3.2 
C-reactive protein, mg/dL < 2 < 2 
Glucose, mg/dL 93.7 ± 5.3 90.2 ± 6.7 
Creatinine, mg/dL 1.1 ± 0.3 1.0 ± 0.2 
AST, U/L 19.2 ± 8.1 22.4 ± 5.3 
ALT, U/L 16.5 ± 6.2 22.1 ± 7.4 
Gamma-GT, U/L 32.3 ± 5.1 29.6 ± 10.3 
Alkaline phosphatase, mU/mL 112 ± 34 89 ± 56 
Total bilirubin, mg/dL 0.73 ± 0.1 0.69 ± 0.2 
Albumin, g/L 3.9 ± 0.2 3.8 ± 0.1 
Treatment for hypertension   
Ca2+ channel blockers 0 12 
β-blockers 0 10 
ACEI 0 12 
Cigarette smokers 0 0 
Alcohol drinking 0 0 
Values are mean ± SD. *P < 0.001. ACEI: angiotensin-converting enzyme 
inhibitors; ALT: alanine aminotransferase; AST: aspartate aminotransferase; 
BMI: body mass index; HDL: high-density lipoprotein.  
 
very strict inclusion criteria were applied as we wanted to 
avoid any confounding patient-related factors. The demo-
graphic and clinical patients data are shown in Table 1. 
2.2  Surgical procedure 
The anesthesia and cardioplegia we used are previously 
described.[28] The operations were all performed by the same 
surgeon. 
Immediately after the start of cardio-pulmonary bypass 
before cardioplegia, a biopsy sample was obtained from the 
right atrium as previously described.[28] There were no clin-
ical complications related to the sampling procedure. The 
samples were fixed in 4% formaldehyde and processed for 
paraffin embedding. 
2.3  Immuno-histochemistry 
Paraffin sections were incubated overnight with poly-
clonal primary anti-Klotho (sc-22220), anti-β-Klotho (sc- 
74343), anti-iNOS (sc-651), anti-eNOS (sc-654), anti- 
GRP78 (sc-1050), anti-TGF-b1 (sc-146), anti-SOD1 (FL-154) 
from Santa Cruz Biotechnology Inc; anti-FGF21 (ab171941) 
from Abcam; anti-FGF23 (bs-5768R) from BiossInc, diluted 
1: 100 with PBS; and monoclonal anti-NF-kB (NB110- 
57266) from Novus Biologicals, diluted 1: 250. The sec-
tions were visualized with a rabbit ABC-peroxidase staining 
system kit (Santa Cruz Biotechnology Inc.). In order to ex-
clude incorrect interpretation of immuno-staining due to 
endogenous biotin, we also carried out experiments using the 
peroxidase-anti-peroxidase detection system. We obtained 
similar results with both methods. The immuno-histochemis-
try control was performed by omitting the primary antibody.  
The staining intensity in both histochemical and im-
muno-histochemistry slides was evaluated using an optical 
microscope equipped with an image analysis program (Im-
ageProPlus 4.5.1). The integrated optical density was calcu-
lated for arbitrary areas, by measuring 10 fields for each 
sample. On sections stained with anti-NF-kB, we also 
counted the percentage of immuno-stained nuclei. 
Collagen density and fibrosis were evaluated using a 
Sirius red staining method,[29] using a light microscope un-
der polarized light. The various thicknesses of collagen fi-
bres showed a different gradient of colours. While the bire-
fringent colour was more a measure of collagen fibre size 
than of collagen type, usually the thicker and denser type I 
collagen fibres ranged from orange to red, whereas the thinner 
type III collagen fibres appeared from yellow to green.[30] 
Different researchers, blinded to the samples, independ-
ently analyzed all slides. 
2.4  Statistical analysis 
The statistical analysis was performed by one-way 
ANOVA followed by the Student-Newman-Keuls test or by 
a Student t-test, and by multivariate regression analysis. A 
value of P < 0.05 was considered statistically significant. 
3  Results 
3.1  Patient demographic and clinical data 
Table 1 shows the demographic and clinical data of pa-
tients studied. Control and HCVR patients were the same 
age and had the same chemical clinical variables. HCVR 
had normal values of blood pressure but all of them were in 
therapy with anti-hypertensive drugs. 
3.2  Higher ASCVD risk influenced the expression of 
Klotho proteins and FGFs 
In the control patients, we observed a very intense cyto-
plasmic immunoreactivity of Klotho and β-Klotho proteins 
uniformly distributed in all cardiomyocytes (Figure1A and 
1D, respectively). In HCVR patients, the Klotho immuno- 
staining intensity was lower. However, some clusters of 
cells show intense staining (Figure 1B). The β-Klotho im-
muno-staining of cells from HCVR patients was uniformly 
diffuse inside the cytoplasm of all cardiomyocytes, but was 
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much lower than that seen in control patients (Figure 1E). 
The optical density value for Klotho and β-Klotho staining was 
resumed in Figure 1C and 1F, respectively. 
Since Klotho is the co-receptor for FGF23 and β-Klotho 
is the co-receptor for FGF21, we also tested the expression 
of these proteins in cardiomyocytes. In the cardiomyocytes 
from control patients, the FGF23 immuno-staining was seen 
to be faint although uniformly diffuse (Figure 2A). Cardio-  
 
Figure 1.  Klotho (A-C) and β-Klotho (D-F) immuno-staining. (A): Control cardiomyocytes show intense cytoplasm staining; (B): car-
diomyocytes from HCVR patients show reduced staining; however, some clusters of cells show intense staining (arrow); (C): relative values 
of optical density according to groups; (D): control cardiomyocytes show intense cytoplasmic staining; (E): the staining is reduced in all 
cardiomyocytes from HCVR patients; and (F): relative values of optical density according to groups. Original magnification 100 ×; scale bar 
= 20 μm; *P < 0.05; **P < 0.01. HCVR: higher cardiovascular risk; IOD: integrated optical density. 
 
Figure 2.  FGF23 (A-C) and FGF21 (D-F) immuno-staining. (A): All control cardiomyocytes show moderate staining; (B): FGF23 
staining increases intensely in cardiomyocytes from HCVR patients; (C): relative values of optical density according to groups; (D): the 
staining in cardiomyocytes from control patients is faint; (E): the staining increased in cells from HCVR patients; and (F): relative values of 
optical density according to groups. Original magnification 100 ×; scale bar = 20 μm; **P < 0.01. HCVR: higher cardiovascular risk; IOD: 
integrated optical density.  
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myocytes from HCVR patients had higher FGF23 staining 
(Figure 2B). The mean optical density for FGF23 staining 
was resumed in Figure 2C. FGF21 immuno-staining from 
control patients showed diffuse but poor staining, which 
was not uniformly distributed inside the cytoplasm (Figure 
2D). In contrast, cardiomyocytes from HCVR patients had 
more intense FGF21 staining, which was uniformly distrib-
uted inside the cytoplasm (Figure 2E). The optical density 
for FGF21 staining was resumed in Figure 2F. 
3.3  Higher ASCVD risk increases ER-stress (GRP78) 
Since depletion of Klotho can promote cell stress, in or-
der to evaluate ER stress and chronic oxidative alterations in 
cardiomyocytes from control and HCVR patients, we also 
detected GRP78 and SOD1. In cardiomyocytes from control 
patients, GRP78 staining intensity was weak to moderate 
and concentrated in cytoplasmic areas, sometimes near the 
nucleus (Figure 3A). In HCVR patients, GRP78 expression 
was higher and mostly concentrated in cytoplasmic areas 
(Figure 3B). Some cardiomyocytes were clustered and in-
tensely stained in certain myocardial areas (Figure 3B, insert). 
The density for GRP78 staining was resumed in Figure 3C. 
SOD1 staining intensity was weakly to moderately in all 
cells from Control patients, and localized only in certain 
cytoplasmic areas (Figure 3D). In contrast, cardiomyocytes 
from HCVR patients showed intense immuno-staining, 
which was uniformly distributed throughout the cytoplasm 
(Figure 3E). The optical density for SOD1 staining was 
resumed in Figure 3F. 
3.4  Higher ASCVD risk increases NF-kB immuno- 
reactivity 
In order to evaluate the inflammatory alterations in car-
diomyocytes from patients, we also detected NF-kB, which 
is a redox regulated transcription factor involved in inflam-
mation, immune function, cellular growth and apoptosis. 
NF-kB was faintly expressed inside the cytoplasm of Con-
trol, and stained nuclei were observed only occasionally 
(Figure 4A). However, cardiomyocytes from HCVR pa-
tients had NF-kB immuno-staining which was intense and 
uniformly distributed not only inside the cytoplasm, but also 
strongly expressed in a large proportion of nuclei (Figure 
4B). Large cardiomyocytes frequently containing debris and 
had large nuclei strongly immuno-stained (Figure 4B insert) 
that sometimes showed “bite-like” signs at pole extremities. 
The quantitative data of stained nuclei is shown in Figure 
4C. The optical density for NF-kB staining is resumed in 
Figure 4D.  
 
Figure 3.  GRP78 (A-C) and SOD1 (D-F) immuno-staining. (A): In cardiomyocytes from Control patients, the staining is weak to mod-
erate and is concentrated in the cytoplasm, sometimes near the nucleus; (B): in cells from HCVR patients, GRP78 staining is more intense. 
Some cells are clustered and much intensely stained (insert); (C): relative values of optical density according to groups; (D): the staining is 
faint to moderate in all cells from Control patients; more intense staining is concentrated in some areas of the cytoplasm; (E): all cardiomyo-
cytes from HCVR patients show intense staining uniformly distributed within the cytoplasm; (F): relative values of optical density according 
to groups. Original magnification 100 ×; scale bar = 20 μm; *P < 0.05; **P < 0.01. GRP78: glucose-regulated protein 78; HCVR: higher 
cardiovascular risk; IOD: integrated optical density; SOD1: superoxide dismutase-1. 
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Figure 4.  NF-kB immuno-staining. (A): Cardiomyocytes from control patients showed a faint signal in the cytoplasm, while the nuclei 
are only stained occasionally (insert). (B): cardiomyocytes from HCVR patients have intense and uniformly distributed NF-kB staining also 
in many nuclei (arrows). Large cardiomyocytes with very pale cytoplasm containing a lot of cellular debris have large strongly stained nuclei 
(insert). (C): percentage of positively NF-kB stained nuclei according to groups. (D): relative values of optical density according to groups. 
Original magnification 200 ×; scale bar = 10 μm; **P < 0.01. HCVR: higher cardiovascular risk; IOD: integrated optical density; NF-KB: 
nuclear factor kappa B.
3.5  Higher ASCVD risk increases iNOS and decreases 
eNOS immuno-reactivity 
The increased presence of ER-stress and oxidative stress 
markers, as well as inflammatory transcription factors in 
cardiomyocytes from HCVR patients, suggests a higher 
production of pro-inflammatory iNOS with reduced expres-
sion of eNOS. iNOS had very weak staining inside the cy-
toplasm of the control (Figure 5A), whereas essentially, all 
HCVR cardiomyocytes showed a moderate to intensely 
stained cytoplasm (Figure 5B). The mean optical density for 
iNOS staining was resumed in Figure 5C. The eNOS stain-
ing was intense in the cytoplasm of cells from control pa-
tients (Figure 5D), but lower in the cells from HCVR pa-
tients (Figure 5E). The optical density for eNOS staining 
was resumed in Figure 5F. 
3.6  Higher ASCVD risk increases fibrosis and TGF-β1 
immuno-reactivity 
The degree of fibrosis was very poor in control patients, 
whereas it was more intense in HCVR cardiomyocytes, with 
a prevalence of thick orange-red fibres instead of thin green 
fibres (Figure 6A and 6B respectively). The density for Sir-
ius-red staining in patient groups was resumed in Figure 6C. 
In line with histochemical data, the density of TGF-β1 
staining, a fundamental protein for collagen synthesis, was 
more intense and uniformly distributed in the cytoplasm of 
cells from HCVR patients (Figure 6E), than in cells from 
control patients (Figure 6D). The optical density for TGF-β1 
staining was resumed in Figure 6F. 
Multivariate regression analysis between klotho and the 
mean variation of other proteins is summarized in Table 2. 
The data shows that the variation of klotho was significantly 
related to the variation of NF-kB, iNOS, and TGF-β1. 
4  Discussion 
This is the first study to show that: (1) Klotho and 
FGF-21/FGF-23 proteins are expressed in human cardio-
myocytes and (2) cardiomyocytes from patients with a 
higher cardiovascular risk disease had reduced expression of 
Klotho but increased expression of FGFs and expression of 
related stress molecules involved in cardiomyocyte damage. 
Until now, Klotho had been shown to be expressed solely 
at the sinoatrial node in mouse hearts, where it is essential 
for the sinoatrial pacemaker function under stress condi-
tions.[31] Here, we have shown expression of Klotho inside 
human cardiomyocytes. However, it should be noted that 
we examined human tissue samples of cardiac atria and 
hence we cannot translate our results to the whole heart, or  
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Figure 5.  iNOS (A-C) and eNOS (D-F) immuno-staining. (A): The staining is very weak in the cytoplasm of cells from Control patients; 
(B): cardiomyocytes from HCVR patients show intensely stained cytoplasm; (C): relative values of optical density according to groups; (D): 
the distribution of staining is uniform and intense in the cytoplasm of cells from Control patients; (E): cells from HCVR patients are faintly to 
moderately stained; and (F): relative values of optical density according to groups. Original magnification 200 ×; scale bar = 10 μm; **P < 
0.01. eNOS: endothelial nitric oxide synthase; HCVR: higher cardiovascular risk; iNOS: inducible nitric oxide synthase; IOD: integrated 
optical density. 
 
Figure 6.  Fibrosis (A-C) and TGF-β1 (D-F) immuno-staining. (A): Control patients samples did not show any abnormal collagen fibres 
deposition. (B): HCVR patients had diffuse fibrosis. Type-I collagen fibres are shown as orange to red, whereas the thinner type-III collagen 
fibres appear yellow to green. (C): Relative values of optical density according to groups. (D): Cell staining from Control patients is faint. (E): 
Immuno-staining from HCVR patient cells is more intense. (F): Relative values of optical density according to groups. Original magnifica-
tion 200 ×; scale bar = 10 μm; **P < 0.01. HCVR: higher cardiovascular risk; IOD: integrated optical density; TGF-β1: transforming growth 
factor-β1. 
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Table 2.  Multivariate regression analysis between klotho and 
mean variation of other proteins. 
 Coefficients Estimate SE t-value P 
Klotho (intercept) 15.41429 0.60353 25.540 0.000  
β-Klotho 0.11435 0.14003 0.817 0.431 
FGF-23 0.06996 0.05776 1.211 0.251 
FGF-21 0.02911 0.08540 0.341 0.740 
SOD1 0.02294 0.06257 0.367 0.721 
NF-kB 0.29199 0.10764 2.713 0.020  
iNOS 0.19065 0.07812 2.441 0.033 
eNOS 0.04104 0.06767 0.607 0.556 
GRP78 0.12325 0.18054 0.683 0.509 
TGF-β1 0.19491 0.06192 3.148 0.009 
eNOS: endothelial nitric oxide synthase; GRP78: glucose-regulated 
protein 78; FGF: fibroblast growth factors; HCVR: higher cardio-
vascular risk; iNOS: inducible nitric oxide synthase; NF-KB: nu-
clear factor kappa B; SOD1: superoxide dismutase-1; TGF-β1: 
transforming growth factor-β1. 
to a peculiar role in the human sinoatrial node. Nonetheless, 
unlike the mouse study, the abundant cytoplasmic expres-
sion of Klotho proteins in human cardiomyocytes of low 
cardiovascular risk atria would strongly suggest the pivotal 
role played by such cardiomyocyte Klotho proteins in whole 
heart physiology. To the best of our knowledge, this is the 
first study that identifies Klotho proteins diffusely and in-
tensely expressed inside the cytoplasm of human cardio-
myocytes. The heart could therefore be regarded not only as 
a target of soluble Klotho produced by other organs, but 
also an organ that produces its own Klotho proteins. In par-
ticular, we have shown that Klotho protein expression is 
blunted in patients with HCVR. Our data agrees with pre-
vious studies showing a correlation between soluble Klotho 
concentration and myocardial diseases.[3,7,32,33] 
Recent studies show the association between circulating 
FGF23 levels and pathologic cardiovascular conditions, 
including left ventricular hypertrophy and vascular endothe-
lial dysfunction.[34–37] 
We did not measure serum concentrations of FGF23, but 
we did demonstrate that cardiomyocytes themselves may 
produce detectable amounts of FGF23 protein and that this 
was higher in HCVR patients. FGF23 is capable of binding 
FGF receptors, although with low affinity, also in the ab-
sence of membrane Klotho. It is therefore plausible that 
activation of FGF receptors also occurs in presence of high 
FGF23 levels in organs where Klotho is absent.[38] We 
therefore believe that cardiac pathophysiology is influenced 
not only by the circulating FGF23, but also by FGF23 pro-
duced by cardiomyocytes themselves and might play an 
important role in metabolic and cardiac functions, perhaps 
through an Klotho-independent way and/or with another 
unknown co-factor. 
Klotho also works as a receptor for FGF21. FGF21, ini-
tially identified as a liver-derived endocrine factor and sub-
sequently found in adipose tissue and muscle,[38] stimulates 
glucose uptake in adipocytes (independently from insulin), 
and has subsequently been related to extension of animal 
life-span.[39,40] Experimental studies have shown that in re-
sponse to ischemia-reperfusion injury to the myocardium, 
FGF21 is up-regulated and released from hepatic cells and 
adipocytes into the circulation. It then interacts with FGFR1 
on cardiomyocytes with β-Klotho, inducing phosphorylation 
of FGFR1. In turn, this reduces apoptosis, cell death and 
myocardial infarction, improving myocardial function.[39,41] 
Serum FGF21 has been found to be higher in patients with 
chronic metabolic and heart diseases. In addition, FGF21 
levels correlate positively with triglyceride, fasting blood 
glucose, apolipoprotein-B100 and insulin resistance, but 
negatively with HDL and apolipoprotein-A1.These findings 
indicate a positive correlation between FGF21 and adverse 
lipid profile in chronic heart disease patients and a possible 
compensatory response or resistance to FGF21.[42] Here, we 
show that FGF21 is over-expressed by cardiomyocytes. 
This would however suggest a possible adaptation or com-
pensatory elevation of FGF21 in order to overcome cardio-
vascular metabolic disorders.[43] 
The intracellular distribution of Klotho mostly overlaps 
with that of the ER and Golgi apparatus,[44] whose expres-
sion has been linked to the ability of cells to withstand stress 
conditions. Indeed, Klotho decreases the GRP78 expression 
and related apoptosis in mice.[10] Our data agree with these 
observations. Indeed, cardiomyocytes from HCVR patients 
had reduced Klotho expression and higher increases of 
GRP78 expression. GRP78 recognizes misfolded proteins 
inside endoplasmic reticulum and dissociates its binding 
from its molecular partners. This in turn triggers the un-
folded protein response by regulating gene responses aimed 
at restoring endoplasmic reticulum proteome stability.[13] 
Failure to promote cell survival by decreasing misfolded 
proteins and oxidative stresses may promote apoptotic cell 
death.[45] 
GRP78 is induced by increased oxidative stress related to 
the inflammatory response, and inflammatory cytokines are 
known to down-regulate Klotho through NF-kB.[21,22] We 
therefore examined the presence and modulation of SOD1, 
iNOS and NF-kB proteins. Our results demonstrated an 
increase of SOD1, iNOS and NF-kB inside the cardiomyo-
cytes from HCVR patients, suggesting a chronic pro-oxida-
tive, pro-inflammatory and pro-apoptotic status. This is in 
line with previous research and shows that there is a correla-
Corsetti G, et al. Klotho expression in patients with CVD 709 
  
http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology  
tion between obesity, diabetes, decrease in Klotho and in-
crease in NF-kB and oxidative stress. In addition, we ob-
served reduced immuno-staining of eNOS in HCVR car-
diomyocytes. Notably, cytoplasmic eNOS improves ener-
getic cellular metabolisms and stimulates mitochondrial 
biogenesis.[46] So, there also exists the possibility of a dis-
ruption of energetic metabolism and altered mitochondrial 
biogenesis in HCVR patients cardiomyocytes. 
Not surprisingly, we detected fibrosis and higher TGF-β1 
expression in cardiomyocytes of HCVR patients. We be-
lieve that the reduced Klotho proteins expression found in 
cardiomyocytes from HCVR patients, could be related to 
the modulation of TGF-β1 synthesis and subsequent fibrosis. 
Indeed, Klotho is able to interfere with TGF-β1 signaling.[24] 
Furthermore, enhanced synthesis of Klotho improves the 
arrangement of cardiomyocytes and myocardial fibres in 
animal models.[10] Although these studies show an associa-
tion between both Klotho deficiency and metabolic and 
cardiac diseases, the cause-effect relationship remains to be 
clarified. 
4.1  Clinical implications 
It is accepted that diabetes, obesity and hypertension are 
risk factors for both coronary calcification and cardiomyo-
cyte pathology. However, the susceptibility, severity and 
progression of cardiovascular diseases are not completely 
explained by these risk factors. Therefore, identification of 
additional molecules involved in the pathophysiology and 
the evolution of cardiovascular diseases is fundamental to 
achieve important objectives such as the development of 
specific new therapies, identification of biomarkers for 
grading cardiovascular risk and monitoring the effects of 
therapy including physical rehabilitation. 
4.2  Limitations 
Certain limitations of this study need to be recognized. 
Firstly, we collected atrial biopsies but atrial tissues were 
considered myocardium and have the same metabolism and 
cellular signaling as the cardiomyocytes. In addition, sam-
pling aimed to provide an appropriate amount of tissue 
without compromising the left ventricular function, and 
consequently the patient’s survival. 
Secondly, only a limited number of patients were en-
rolled in this study. The patients were however very highly 
selected to avoid any confounding co-morbidity and, in ad-
dition, the sample was adequate for us to identify the major 
relationship between Klotho and related protein presence 
and cardiovascular risk.  
Thirdly, we only used immuno-histochemistry to support 
our results. This was dictated by the rules in force in our 
operating theatre, which excluded the possibility of using 
liquid nitrogen and then immediately freeze the biopsies for 
molecular biology evaluations. However, although the im-
muno-histochemistry does not quantify molecules as accu-
rately as molecular biology, we believe that this technique 
has certain advantages. Indeed, the standard fixation main-
tains the architecture of the tissue, allowing adequate mor-
phological assessments. In addition, immuno-histochemistry 
allows us to localize the analyzed molecules both between 
different cells types and inside the cells. In contrast, mo-
lecular biology requires immediate freezing and homogeni-
zation of the sample. As a consequence, it does not take into 
account the specificities of the location of immuno-staining, 
and so the morphology of the tissue.  
4.3  Conclusions 
In conclusion, we have reported for the first time the 
presence of Klotho proteins in human hearts in vivo, and 
that HCVR cardiomyocytes have deranged expressions of 
Klotho, FGF23, FGF21 and related stress molecules in-
volved in cellular injury. We believe that modulation of 
these molecules could play a pivotal role in heart patho-
physiology. We therefore suggest that preventing the Klotho 
decrease or promoting its increase, and/or FGFs modulation 
inside cardiomyocytes, could prevent and/or reduce cardio-
vascular diseases in high risk patients. 
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